NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company’s enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The calcium salt patent expires in July 2010. The patent was challenged by generic manufacturer Lek Pharmaceuticals D.D., and is one of four separate challenges to the calcium salt patent by generic companies in Spain.
